Ignite Creation Date:
2024-05-06 @ 1:39 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04084509
Status:
WITHDRAWN
Last Update Posted:
2020-04-06
First Post:
2019-08-08
Brief Title:
Molecular and Functional Imaging in SNCA Parkin and PINK1
Sponsor:
Kings College London
Organization:
Kings College London
Study Overview
Official Title:
Molecular and Functional Imaging of Parkinsons Pathology in SNCA Parkin and PINK1 Mutation Carriers
Status:
WITHDRAWN
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Change of circumstances for CIPI
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Parkinsons Disease PD is a progressive neurodegenerative disease characterized clinically by bradykinesia resting tremor rigidity and postural instability The hallmark pathophysiological alteration is a loss of dopaminergic transmission across the nigrostriatal pathway According to Braaks neuropathological staging of disease the pathological process in PD occurs in a gradual ascending fashion starting from the olfactory bulb and progressing to the brainstem with preferential involvement of the raphe nuclei which contain serotonergic nuclei and the noradrenergic locus coeruleus before involving the substantia nigra and thereafter the whole brain Little is known about the mechanisms underlying neuronal degeneration in PD and currently no treatment is available to halt disease progression in PD The pathophysiological characterisation of phenomena occurring in the time window between the pathological start of the disease and the onset of motor symptoms is crucial to develop potential neuroprotective agents Several genes causing the so-called monogenic parkinsonism have been discovered providing important insights on the pathogenesis of PD
The objective of the study is to characterize the molecular phenomena underlying genetic forms of parkinsonism and therefore providing further insights about the possible mechanisms taking place in PD and help identify targets for disease-modifying therapeutics by using PET imaging with 11CDASB a marker of Serotonin transporter SPECT imaging using 123IFP-CIT a marker of the presynaptic Dopamine transporter and multi-modal MRI imaging clinical markers motor and non-motor symptoms and neuropsychological battery blood and CSF biomarkers
The objective of the study is to characterize the molecular phenomena underlying genetic forms of parkinsonism and therefore providing further insights about the possible mechanisms taking place in PD and help identify targets for disease-modifying therapeutics by using PET imaging with 11CDASB a marker of Serotonin transporter SPECT imaging using 123IFP-CIT a marker of the presynaptic Dopamine transporter and multi-modal MRI imaging clinical markers motor and non-motor symptoms and neuropsychological battery blood and CSF biomarkers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None